Lipum Investor Relations Material
Latest events
Q1 2025
Lipum
Q1 2025
24 Apr, 2025
Q4 2024
26 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lipum
Access all reports
Lipum is a biotechnology company focused on developing novel treatments for chronic inflammatory diseases. Its research targets specific proteins involved in inflammation pathways, with the aim of developing biological drug candidates for autoimmune conditions. The company is headquartered in Umeå, Sweden, and its shares are listed on the Nasdaq First North Growth Market.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
LIPUM
Country
🇸🇪 Sweden